Trial News: AGITG update on trials

AGITG Trial news: The AGITG currently has nineteen studies open to recruitment and three studies in follow up.

The table below details the AGITG trials that are currently accruing patients.

	Recruited	Target	Recruitment Period (months)	Date of First Site Open (ANZ)	Number of Sites Open
ACTICCA-1 (Cholangiocarcinoma)	29	40	72	25 July 2016	13
ASCOLT (Colorectal cancer)	466	460	48	18 June 2014	32
ASCOLT – Global	1569	1587
DYNAMIC-III (Colon cancer)	501	1000	54	09 October 2017	41
DYNAMIC-Pancreas (Pancreatic cancer)	67	438	54	01 March 2019	26
DYNAMIC-Rectal (Rectal cancer)	202	408	36	18 June 2018	37
FORECAST-1 (Colorectal cancer)	26	30	12	11 September 2020	4
GENESCREEN 5-FU (Pan Tumour)	11	50	50	1 February 2021	2
INTEGRATE II (Gastro-oesophageal cancer)	77	90	48	19 October 2016	27
INTEGRATE II – Global	229	350			64
LICPIC (Colorectal cancer)	39	100	110	11 September 2018	2
MASTERPLAN (Pancreatic cancer)	12	120	48	01 October 2019	9
MONARCC (Colorectal cancer)	32	80	24	20 June 2018	21
NABNEC (Neuroendocrine tumours)	49	58	54	15 September 2016	18
OXTOX (Colorectal cancer)	2	100	18	18 December 2020	3
PALEO (Oesophageal cancer)	5	54	36	16 September 2019	1
RANDOMS (Pancreatic cancer)	2	60	48	14 December 2020	3
RENO (Rectal cancer)	32	250	36	21 January 2019	7
SPAR (Rectal cancer)	76	222	48	13 April 2018	15
TOP GEAR (Gastric & gastro-oesophageal cancer)	242	280	118	29 September 2009	27
TOP GEAR – Global	565	570			41

Recruitment figures are for Australian and New Zealand sites as at end March 2021.

AGITG Trial News